Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.

J Clin Med · 2022 · PMC9032972 · PMID 35456332

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In fact, two- and three-year survival rates showed a positive trend in the ipilimumab plus nivolumab -> encorafenib plus binimetinib (arm B: 73% and 62%, respectively) sequence and with the sandwich strategy (arm C: 69% and 60%, respectively) compared with encorafenib plus binimetinib -> ipilimumab plus nivolumab (arm A: 65% and 54%, respectively).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.